Evidence map›Paper›PMID 37433892›Full record

ArticleEuropean journal of human genetics : EJHG2023

At a glance: the largest Niemann-Pick type C1 cohort with 602 patients diagnosed over 15 years.

Pilar Guatibonza Moreno, Luba M Pardo, Catarina Pereira, Sabine Schroeder, Deepthi Vagiri, Ligia S Almeida, Carlos Juaristi, Heba Hosny, Clarice C Y Loh, Anika Leubauer and 12 more

Abstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Generation and characterization of human iPSC-derivedbioRxiv : the preprint server for biology · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Expanding what we know about rare genetic diseases.European journal of human genetics : EJHG · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Pilar Guatibonza Moreno *CENTOGENE GmbH, Rostock, Germany.
Luba M Pardo *CENTOGENE GmbH, Rostock, Germany.
Catarina PereiraCENTOGENE GmbH, Rostock, Germany.
Sabine SchroederCENTOGENE GmbH, Rostock, Germany.
Deepthi VagiriCENTOGENE GmbH, Rostock, Germany.
Ligia S AlmeidaCENTOGENE GmbH, Rostock, Germany.
Carlos JuaristiCENTOGENE GmbH, Rostock, Germany.
Heba HosnyCENTOGENE GmbH, Rostock, Germany.ORCID 0000-0003-1447-6459
Clarice C Y LohCENTOGENE GmbH, Rostock, Germany.
Anika LeubauerCENTOGENE GmbH, Rostock, Germany.ORCID 0000-0001-8402-5448
Galina Torres MoralesCENTOGENE GmbH, Rostock, Germany.
Sebastian OppermannCENTOGENE GmbH, Rostock, Germany.
Marius-Ionuț IurașcuCENTOGENE GmbH, Rostock, Germany.ORCID 0000-0003-3791-7050
Steffen FischerCENTOGENE GmbH, Rostock, Germany.ORCID 0000-0002-9821-2313
Tara-Marisa SteinickeCENTOGENE GmbH, Rostock, Germany.
Nikenza ViceconteCENTOGENE GmbH, Rostock, Germany.
Claudia CozmaCENTOGENE GmbH, Rostock, Germany.ORCID 0000-0001-9841-1104
Krishna Kumar KandaswamyCENTOGENE GmbH, Rostock, Germany.
Jorge Pinto BastoCENTOGENE GmbH, Rostock, Germany.
Tobias BöttcherCENTOGENE GmbH, Rostock, Germany.
Peter BauerCENTOGENE GmbH, Rostock, Germany. Peter.Bauer@centogene.com.ORCID 0000-0001-9414-4555
Aida Bertoli-AvellaCENTOGENE GmbH, Rostock, Germany.ORCID 0000-0001-9544-1877

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Niemann-Pick type C1 disease (NPC1 [OMIM 257220]) is a rare and severe autosomal recessive disorder, characterized by a multitude of neurovisceral clinical manifestations and a fatal outcome with no effective treatment to date. Aiming to gain insights into the genetic aspects of the disease, clinical, genetic, and biomarker PPCS data from 602 patients referred from 47 countries and diagnosed with NPC1 in our laboratory were analyzed. Patients' clinical data were dissected using Human Phenotype Ontology (HPO) terms, and genotype-phenotype analysis was performed. The median age at diagnosis was 10.6 years (range 0-64.5 years), with 287 unique pathogenic/likely pathogenic (P/LP) variants identified, expanding NPC1 allelic heterogeneity. Importantly, 73 P/LP variants were previously unpublished. The most frequent variants detected were: c.3019C > G, p.(P1007A), c.3104C > T, p.(A1035V), and c.2861C > T, p.(S954L). Loss of function (LoF) variants were significantly associated with earlier age at diagnosis, highly increased biomarker levels, and a visceral phenotype (abnormal abdomen and liver morphology). On the other hand, the variants p.(P1007A) and p.(S954L) were significantly associated with later age at diagnosis (p < 0.001) and mildly elevated biomarker levels (p ≤ 0.002), consistent with the juvenile/adult form of NPC1. In addition, p.(I1061T), p.(S954L), and p.(A1035V) were associated with abnormality of eye movements (vertical supranuclear gaze palsy, p ≤ 0.05). We describe the largest and most heterogenous cohort of NPC1 patients published to date. Our results suggest that besides its utility in variant classification, the biomarker PPCS might serve to indicate disease severity/progression. In addition, we establish new genotype-phenotype relationships for "frequent" NPC1 variants.

Indexed as

PhenotypeAdolescentAdultChildChild, PreschoolHumansInfantInfant, NewbornMiddle AgedYoung Adult

Identifiers

PMID37433892
PMCPMC10545733

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.